Highlights

  • Arovella Therapeutics Ltd (ASX: ALA) closed at $0.061 on August 7, 2026.
  • The stock recorded an increase of approximately 1.67 percent for the session.
  • Shares traded within an intraday range of $0.061 to $0.063.
  • Market capitalisation stood at approximately $73.74 million.
  • Trading volume reached 460,485 shares during the session.

Arovella Therapeutics Ltd (ASX: ALA) shares closed at $0.061 on August 7, 2026, after recording an increase of approximately 1.67 percent during the session. The stock traded within an intraday range of $0.061 to $0.063, while the broader S&P/ASX 200 Health Care Index ended lower after declining 0.92 percent.

Arovella Therapeutics Share Price Movement on August 7, 2026

The data reviewed showed that Arovella Therapeutics shares recorded an increase of approximately 1.67 percent during the session. The stock traded between an intraday low of $0.061 and a high of $0.063 before closing at $0.061.

Daily share price movements in biotechnology companies can vary depending on company-specific developments, trading activity, sector sentiment and broader market conditions. The session’s movement represents short-term market activity and should be viewed alongside longer-term performance trends.

Trading Volume and Market Capitalisation

Trading volume for Arovella Therapeutics reached 460,485 shares during the session. Based on the closing share price, the company’s market capitalisation stood at approximately $73.74 million.

The trading volume reflected market participation during the session, while the company’s market capitalisation placed it among the smaller-capitalisation companies within the ASX health care sector.

One-Year Share Price Performance

Over the trailing one-year period, Arovella Therapeutics recorded a decline of approximately 39.00 percent based on the data reviewed.

Biotechnology companies can experience share price movements over time due to factors including company-specific developments, research and development activities, funding requirements, market expectations and broader investor sentiment toward the sector.

ASX Health Care Sector Performance

The broader S&P/ASX 200 Health Care Index (XHJ) closed at 27,976.2 points on August 7, 2026, down 259.3 points or 0.92 percent.

The index recorded a day high of 28,235.5 points and a day low of 27,808.8 points, compared with a previous close of 28,235.5 points. Over the past 52 weeks, the index traded between 21,947.2 and 45,579.6 points, with a one-year return of negative 37.44 percent.

Individual health care stocks can record movements that differ from the broader index due to company-specific factors, trading volumes and changes in investor participation.

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd is listed on the ASX under the ticker code ALA and operates within the health care sector.

Companies operating within biotechnology can experience share price movements influenced by research developments, company updates, sector conditions and broader market trends.

Understanding the Trading Data

The share price, trading volume and market capitalisation figures provide an overview of Arovella Therapeutics’ market activity during the reviewed session.

Trading volume represents the number of shares exchanged during the session, while market capitalisation reflects the market value based on the closing share price and shares on issue. Daily price movements represent activity during a specific trading period and do not necessarily indicate longer-term performance.

Conclusion

Arovella Therapeutics Ltd (ASX: ALA) shares closed at $0.061 on August 7, 2026, after recording an increase of approximately 1.67 percent during the session. The stock traded within a range of $0.061 to $0.063, with trading volume of 460,485 shares and market capitalisation of approximately $73.74 million.

The broader S&P/ASX 200 Health Care Index closed lower at 27,976.2 points, down 0.92 percent. Over the trailing one-year period, Arovella Therapeutics recorded a decline of approximately 39.00 percent based on the data reviewed.